Lupin seeds research accord with Medicis while settling Solodyn dispute
This article was originally published in Scrip
Executive Summary
Lupin continues to make strides in monetising its drug delivery platform technologies. The Indian company has now entered into an R&D agreement with the US specialty firm, Medicis Pharmaceutical, for the application of certain proprietary formulation technologies to a range of compounds.